MetaVia MTVA
NASDAQ MTVA
$1.46 +0.02 (+1.39%)
At close: Aug 21, 2026 · 4:00 PM EDT

MetaVia (MTVA) Liabilities and Shareholders Equity (2015 - 2026)

MetaVia's (MTVA) quarterly Liabilities and Shareholders Equity came in at $11.1 million in Q4 2025, down 31.59% YoY from $16.3 million in Q4 2024, and down 24.67% on a QoQ basis from $14.8 million in Q3 2025.

MetaVia (MTVA) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends

MetaVia (MTVA) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $11.1 million in Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 31.59% year-over-year to $11.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $56.5 million (down 32.91% YoY) and the FY2025 annual result came in at $11.1 million, down 31.59% from the prior year.
  • Liabilities and Shareholders Equity slipped to $11.1 million in Q4 2025, from $14.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $33.5 million in Q4 2022 to a low of $7.6 million in Q3 2022.
  • A 5-year average of $18.2 million and a median of $16.5 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 249.68% — and 2024, when it plunged 45.95%.
  • Tracing MTVA's Liabilities and Shareholders Equity over 5 years: stood at $16.8 million in 2021, then jumped by 99.62% to $33.5 million in 2022, then sank by 32.07% to $22.8 million in 2023, then slipped by 28.62% to $16.3 million in 2024, then tumbled by 31.59% to $11.1 million in 2025.
  • The last three Liabilities and Shareholders Equity figures came in at $11.1 million (Q4 2025), $14.8 million (Q3 2025), and $18.5 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 MetaVia 8.72 Mn -3.92 Mn - 13.27 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 13.27 Mn
Dec 31, 2025 11.12 Mn
Sep 30, 2025 14.77 Mn
Jun 30, 2025 18.46 Mn
Mar 31, 2025 12.13 Mn
Dec 31, 2024 16.26 Mn
Sep 30, 2024 22.15 Mn
Jun 30, 2024 28.75 Mn
Mar 31, 2024 17.02 Mn
Dec 31, 2023 22.78 Mn
Sep 30, 2023 26.43 Mn
Jun 30, 2023 29.18 Mn
Mar 31, 2023 31.49 Mn
Dec 31, 2022 33.53 Mn
Sep 30, 2022 7.56 Mn
Jun 30, 2022 10.08 Mn
Mar 31, 2022 13.46 Mn
Dec 31, 2021 16.80 Mn
Sep 30, 2021 8.08 Mn
Jun 30, 2021 10.72 Mn